Skip to main content

Advertisement

Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Fig. 2

Cox proportional hazard models for primary and secondary endpoints in the patients with diabetes mellitus and diabetic foot. The probability of mortality and cardiovascular outcomes in the patients with diabetes mellitus and diabetic foot is shown for the DPP4i-only or insulin-only group versus the combined therapy group. The effects of DPP4i-only and insulin-only therapy on MACEs, nonfatal MI, nonfatal stroke, cardiac death, death resulting from any cause, amputation and heart failure for admission were analyzed individually. DPP4i dipeptidyl peptidase-4 inhibitor, HR hazard ratio, CI confidence interval, MACE major adverse cardiac event, MI myocardial infarction

Back to article page